Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Dilip Shanghvi to continue as the Executive Chairman of the Board
This strategic expansion marks a significant step in the company's global growth strategy
25 women students to receive internship, training, and mentorship in Life Sciences segment
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Subscribe To Our Newsletter & Stay Updated